ImmunoCellular Therapeutics announces long-term text from ICT-107 Stage I clinical checking with a view GBM
Posted in Drug Trial on September 8th, 2010ImmunoCellular Therapeutics (OTCBB: IMUC), a biotechnology callers focused on the circumstance of unfamiliar immune-based cancer therapies, today announced long-term figures from a Point of view I clinical essay of ICT-107, the Company’s possibility cancervaccine seeker in requital for the treatment of glioblastoma multiforme (GBM), the most customary and assertive convention of braincancer. The evidence usher six tired of 16 (37.6%) patients Read the rest of this entry »
